GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GRI Bio Inc (NAS:GRI) » Definitions » Total Current Liabilities

GRI Bio (GRI Bio) Total Current Liabilities : $1.68 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is GRI Bio Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. GRI Bio's total current liabilities for the quarter that ended in Mar. 2024 was $1.68

GRI Bio Total Current Liabilities Historical Data

The historical data trend for GRI Bio's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GRI Bio Total Current Liabilities Chart

GRI Bio Annual Data
Trend Dec21 Dec22 Dec23
Total Current Liabilities
4.88 1.99 2.70

GRI Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.07 1.60 2.18 2.70 1.68

GRI Bio Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

GRI Bio's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.68+0.014
+Other Current Liabilities+Current Deferred Liabilities
=0.0030000000000001+0
=2.70

GRI Bio's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.636+0.043
+Other Current Liabilities+Current Deferred Liabilities
=0.0010000000000001+0
=1.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

GRI Bio Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of GRI Bio's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

GRI Bio (GRI Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GRI Bio Inc (NAS:GRI) » Definitions » Total Current Liabilities
Comparable Companies
ELOX SXTP ARTL PTIX ARDS PSTV QLGN APVO NEXI FWBI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037
Website
https://www.gribio.com
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.
Executives
David Leslie Szekeres director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT, SUITE 210, SAN DIEGO CA 92121
Roelof Rongen director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Camilla V Simpson director 20 ELAINE AVE., MILL VALLEY CA 94941
Albert Agro officer: Chief Medical Officer 828 RICHMOND STREET WEST, TORONTO A6 M6J 1C9
Walter Marc Hertz director, 10 percent owner, officer: Chief Executive Officer 2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Vipin Chaturvedi officer: Chief Scientific Officer 2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Meenu Chhabra director C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Joseph E Payne director 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Leanne M. Kelly officer: Chief Financial Officer C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Marella Thorell director 1226 CHARTER LANE, AMBLER PA 19002
Arcturus Therapeutics Holdings Inc. 10 percent owner 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Penny Toren officer: SVP, Regul Affairs & Prog Mgmt C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Ofir Levi director C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Richard Ammer director, 10 percent owner C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Pharma Gmbh Salmon 10 percent owner SANKT-JACOBS-STRASSE 90, CH-9002, BASEL V8 4052

GRI Bio (GRI Bio) Headlines

From GuruFocus

GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression

By Marketwired • 10-17-2023

GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus

By ACCESSWIRE • 08-25-2023

September Is Pulmonary Fibrosis Awareness Month: Here's What One Company Is Doing To Develop A Treatment For This Deadly Disease

By ACCESSWIRE • 09-29-2023

GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR

By Marketwired • 08-23-2023

GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference

By Marketwired • 10-19-2023

GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio

By Marketwired • 06-27-2023

GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions

By Marketwired • 10-05-2023

Thinking about buying stock in Alarum Technologies, GRI Bio, Ideanomics, NRX Pharmaceuticals, or Nextgen Food Robotics?

By PRNewswire • 08-28-2023

GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website

By sperokesalga sperokesalga • 06-13-2023

GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference

By Marketwired • 09-06-2023